🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs
4,713

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Page 9 of 99

  1. A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)

    Merck Sharp and Dohme

    Systemic lupus erythematosus, Rheumatoid arthritis

    phase 1 other active

    1 trial

  2. A clinical study of MK-1289 in healthy adult men (MK-1289-001)

    Merck Sharp and Dohme

    COVID-19 Infection

    phase 1 other active

    1 trial

  3. A clinical study of MK-1403 in healthy men (MK-1403-004)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  4. A clinical study of MK-1403 in healthy people (MK-1403-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  5. A clinical study of MK-2420 in healthy men (MK-2420-003)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  6. A clinical study of MK-2420 in healthy people (MK-2420-002)

    Merck Sharp and Dohme

    Rheumatoid arthritis

    phase 1 other active

    1 trial

  7. A clinical study of MK-2828 in healthy people (MK-2828-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  8. A clinical study of MK-2828 in healthy people (MK-2828-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  9. A clinical study of MK-3214 in healthy people (MK-3214-001)

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  10. A clinical study of MK-3508 in healthy people (MK-3508-006)

    Merck Sharp and Dohme

    Respiratory syncytial virus infection

    phase 1 other active

    1 trial

  11. A clinical study of MK-4082 in healthy people (MK-4082-001)

    Merck Sharp and Dohme

    Weight management

    phase 1 other active

    1 trial

  12. A clinical study of MK-4646 in healthy people (MK-4646-002)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  13. A clinical study of MK-4646 in people with HIV (MK-4646-003)

    Merck Sharp and Dohme

    HIV infection

    phase 1 other active

    1 trial

  14. A clinical study of MK-5661 and placebo in healthy people (MK-5661-006)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  15. A clinical study of MK-5661 in healthy people (MK-5661-007)

    Merck Sharp and Dohme

    Pain

    phase 1 other active

    1 trial

  16. A clinical study of MK-6050 in healthy people (MK-6050-001)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  17. A clinical study of MK-6916 and placebo in healthy people (MK-6916-003)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  18. A clinical study of MK-6916 in healthy people (MK-6916-002)

    Merck Sharp and Dohme

    Acute and Chronic Pain

    phase 1 other active

    1 trial

  19. A clinical study of MK-6916 in healthy people (MK-6916-006)

    Merck Sharp and Dohme

    Acute and chronic Pain

    phase 1 other active

    1 trial

  20. A clinical study of MK-7228 in healthy men (MK-7228-001)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  21. A clinical study of the V540A vaccine in healthy adults (V540A-001)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  22. A clinical study of the V540C vaccine in healthy adults (V540C-003)

    Merck Sharp and Dohme

    Human Papilloma virus

    phase 1 other active

    1 trial

  23. A clinical study to evaluate the efficacy of ceritinib in combination with nivolumab in patients with ALK positive lung cancer

    Novartis Pharmaceuticals

    Non-small cell lung cancer

    phase 1 other active

    1 trial

  24. A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors

    Pierre Fabre Medicament

    Participants with BRAF and/or NRAS mutation positive tumors

    phase 1 other active

    1 trial

  25. A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

    Stemline Therapeutics B.V.

    ​​Platinum-Resistant ovarian cancer​

    phase 1 other active

    1 trial

  26. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  27. A clinical trial investigating the safety and biological activity of the antibody BNT351 in adults living without and with HIV

    BioNTech SE

    HIV-1 infection

    phase 1 other active

    1 trial

  28. A clinical trial of MK-1824 in healthy participants (MK-1824-001)

    Merck Sharp and Dohme

    Heart failure with preserved ejection fraction

    phase 1 other active

    1 trial

  29. A clinical trial of MK-3214 taken with different liquids in healthy participants (MK-3214-002)

    Merck Sharp and Dohme

    Hypercholesterolaemia

    phase 1 other active

    1 trial

  30. A clinical trial of MK-4605 in healthy participants (MK-4605-001)

    Merck Sharp and Dohme

    Dementia

    phase 1 other active

    1 trial

  31. A clinical trial of MK-6050 in healthy participants (MK-6050-002)

    Merck Sharp and Dohme

    Hidradenitis suppurativa

    phase 1 other active

    1 trial

  32. A clinical trial of MK-6916 in healthy participants (MK-6916-010)

    Merck Sharp and Dohme

    Acute and Chronic pain

    phase 1 other active

    1 trial

  33. A clinical trial of MK-7228 in adults (MK-7228-002)

    Merck Sharp and Dohme

    Atherosclerosis

    phase 1 other active

    1 trial

  34. A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  35. A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  36. A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer

    Novartis Pharmaceuticals

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  37. A clinical trial to look at how ZN-A-1041 alone or ZN-A-1041 plus some approved drugs works to reduce tumor size and how safe these drugs are at different doses.

    Hoffmann-La Roche

    HER2-positive advanced solid tumours

    phase 1 other active

    1 trial

  38. A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis

    Philogen S.p.A.

    Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

    phase 1 other active

    1 trial

  39. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  40. A double blinded, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine Delayed Release Tablets USP 1.2 g manufactured by Sun Pharmaceutical Industries Limited, India with Mezavant (mesalamine) Delayed and Extended-Release Tablets 1.2 g product of Takeda Canada Inc., in healthy, adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    ulcerative colitis

    phase 1 other active

    1 trial

  41. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    major depressive illness

    phase 1 other active

    1 trial

  42. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fed condition.

    Lacuna Pharma Pty Ltd

    major depressive illness

    phase 1 other active

    1 trial

  43. A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 10 mg, manufactured by Ohm Laboratories Inc. (A Sun Pharma Company), 14 Terminal Road, New Brunswick, 08901, NJ, USA with Vyvanse (Lisdexamfetamine Dimesylate) 10 mg capsules; Product of Takeda Canada Inc., Toronto Ontario ON M5H 4E3, Canada, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    ADHD

    phase 1 other active

    1 trial

  44. A double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of briquilimab in participants with allergic asthma.

    Jasper Therapeutics

    allergic asthma

    phase 1 other active

    1 trial

  45. A drug-drug interaction trial in healthy female participants to investigate the effect of aprocitentan on combined hormonal contraceptives.

    Lacuna Pharma Pty Ltd

    Not applicable - healthy volunteer trial

    phase 1 other active

    1 trial

  46. A first human dose study to assess the safety, tolerability, pharmacokinetics and target engagement of single doses of NNC6022-0001 in healthy adults

    NovoThirteen

    Cardiometabolic diseases

    phase 1 other active

    1 trial

  47. A first in human study of people with chronic hepatitis B, where all participants will receive the new drug PBGENE-HBV. This study will use increasing dose amounts of the drug to see how safe and bearable it is. The study will also test how well PBGENE-HBV works and how it is processed by the body.

    Chongqing Precision Biotech Co., Ltd

    Chronic Hepatitis B

    phase 1 other active

    1 trial

  48. A first-in-human study to investigate safety and tolerability of SAR446959 in participants with osteoarthritis of the knee

    Sanofi-aventis Healthcare Pty Ltd

    Osteoarthritis

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.